Table 3.
Baseline Data of High-Risk Group and Low-Risk Group in External Validation Set of Clinical Prognosis Model
| High cp-Risk | Low cp-Risk | p | |
|---|---|---|---|
| Feature | n=462 | n=493 | |
| Futime (mean (SD)) | 957.05 (869.67) | 1808.66 (996.49) | <0.001 |
| Fustat (%) | <0.001 | ||
| Death | 138 (29.9) | 349 (70.8) | |
| Alive | 324 (70.1) | 144 (29.2) | |
| Age (%) | <0.001 | ||
| < 70 | 105 (22.7) | 44 (8.9) | |
| ≥70 | 357 (77.3) | 449 (91.1) | |
| Gender (%) | 0.742 | ||
| Female | 332 (71.9) | 360 (73.0) | |
| Male | 130 (28.1) | 133 (27.0) | |
| Primary (%) | 0.021 | ||
| Cardia | 42 (9.1) | 35 (7.1) | |
| Fundus of stomach | 11 (2.4) | 10 (2.0) | |
| Body of stomach | 62 (13.4) | 65 (13.2) | |
| Gastric antrum | 207 (44.8) | 257 (52.1) | |
| Pylorus | 20 (4.3) | 31 (6.3) | |
| Lesser curvature of stomach | 20 (4.3) | 29 (5.9) | |
| Greater curvature of stomach | 4 (0.9) | 6 (1.2) | |
| Overlapping lesion of stomach | 95 (20.6) | 59 (12.0) | |
| Stomach-NOS | 1 (0.2) | 1 (0.2) | |
| Grade (%) | <0.001 | ||
| Well differentiated | 1 (0.2) | 10 (2.0) | |
| Moderately differentiated | 66 (14.3) | 121 (24.5) | |
| Poorly differentiated | 394 (85.3) | 361 (73.2) | |
| Undifferentiated | 1 (0.2) | 1 (0.2) | |
| Histologic (%) | 0.159 | ||
| Adenocarcinomas | 407 (88.1) | 453 (91.9) | |
| Signet ring cell carcinoma | 11 (2.4) | 14 (2.8) | |
| Mucinous adenocarcinoma | 35 (7.6) | 21 (4.3) | |
| Adenosquamous carcinoma | 1 (0.2) | 0 (0.0) | |
| Squamous cell carcinoma | 4 (0.9) | 1 (0.2) | |
| Carcinoid | 1 (0.2) | 0 (0.0) | |
| Other classes | 3 (0.6) | 4 (0.8) | |
| Clinical Stage (%) | <0.001 | ||
| Stage I | 2 (0.4) | 217 (44.0) | |
| Stage II | 66 (14.3) | 174 (35.3) | |
| Stage III | 288 (62.3) | 95 (19.3) | |
| Stage IV | 106 (22.9) | 7 (1.4) | |
| T Stage (%) | <0.001 | ||
| T1 | 4 (0.9) | 88 (17.8) | |
| T2 | 157 (34.0) | 281 (57.0) | |
| T3 | 241 (52.2) | 117 (23.7) | |
| T4 | 60 (13.0) | 7 (1.4) | |
| N Stage (%) | <0.001 | ||
| N0 | 21 (4.5) | 264 (53.5) | |
| N1 | 146 (31.6) | 172 (34.9) | |
| N2 | 211 (45.7) | 56 (11.4) | |
| N3 | 84 (18.2) | 1 (0.2) | |
| M Stage (%) | 0.655 | ||
| M1 | 457 (98.9) | 490 (99.4) | |
| M0 | 5 (1.1) | 3 (0.6) | |
| RNE(%) | 0.002 | ||
| < 15 | 223 (48.3) | 189 (38.3) | |
| ≥15 | 239 (51.7) | 304 (61.7) | |
| LNMR (%) | <0.001 | ||
| 0 | 20 (4.3) | 263 (53.3) | |
| <30% | 87 (18.8) | 228 (46.2) | |
| ≥30% and <70% | 213 (46.1) | 2 (0.4) | |
| ≥70% | 142 (30.7) | 0 (0.0) |